Preferences help
enabled [disable] Abstract
Number of results
2014 | 9 | 1 | 80-85
Article title

Inclusion body myositis - a case based clinicopathological update

Title variants
Languages of publication
Inclusion body myositis is a slowly progressive myopathy affecting predominantly the middle-aged and older patient population. It is a major form of the idiopathic inflammatory myopathies which are chronic systemic autoimmune diseases characterized by symmetrical proximal muscle weakness. Unfortunately, there is no effective therapy yet; however, the early diagnosis is essential to provide treatment options which may significantly slow the progression of the disease. In our case-based clinicopathological study the importance of the close collaboration between the clinician and the neuropathologist is emphasised.
Physical description
1 - 2 - 2014
4 - 2 - 2014
  • [1] Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–347[Crossref]
  • [2] Benveniste O. et al. International Workshop on Inclusion Body Myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord. 2010;20:414–421[Crossref]
  • [3] Greenberg SA. Pathogenesis and therapy of inclusion body myositis. Curr Opin Neurol. 2012;25:630–639[WoS][Crossref]
  • [4] Askanas V. et al. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 2011;40(4 Pt 2):e219–235[Crossref]
  • [5] Murnyák B., and Bodoki L. et al. Inclusion body myositis - pathomechanism and lessons from genetics 2013. (Cent Eur J Med. 2013 submitted for publication)
  • [6] Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep. 2010;12:221–228[Crossref]
  • [7] Váncsa A. et al. [Inclusion body myositis pathomechanism and therapy]. [Article in Hungarian]. Orv Hetil. 2008;149:1413–1418[Crossref]
  • [8] Quick A. et al. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 2011;13:192–198[Crossref]
  • [9] Kierdaszuk B. et al. Inclusion body myositis: therapeutic approaches. A case report. Neurol Neurochir Pol. 2011;45:68–73
  • [10] Dziadzio M. et al. Common variable immunodeficiency with coexisting central nervous system sarcoidosis. Case report and literature review with implications for diagnosis and pathogenesis. Ideggyogy Sz 2011;64:405–408
  • [11] Csonka T. et al. The diagnosis of herpes encephalitis- a case-based update. Ideggyogy Sz 2013 (in press)
  • [12] Rider LG. et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010 Apr;62(4):465–72. doi: 10.1002/acr.20035[Crossref][WoS]
  • [13] Kendall FP. Et al. Muscles: testing and function. 4th ed. Baltimore: Williams and Wilkins; 1993
  • [14] Rider LG. et al. International Myositis Assessment and Clinical Studies Group, International Consensus On Preliminary Definitions of Improvement for Adult and Juvenile Myositis, Arthritis Rheum., 2004 Jul, 50(7):2281–2290[Crossref]
  • [15] Cox FM. et al. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology (Oxford). 2011;50:1153–1161[Crossref][WoS]
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.